Does personalized medicine cut the mustard when it comes to treating cancer? Richard Smith, a former editor of the British Medical Journal, believes that it does not. Using the mustard metaphor, he shows how personalized medicine undermines the pharmaceutical industry’s profits. If the one-size-fits-all approach to prescribing cancer drugs were abandoned, drug companies would be forced to change their business model, most notably by increasing prices radically – or stop producing the drugs altogether.
View the original article here: Personalized Medicine’s Perverse Economics
Personalized medicine’s perverse economics
Donna Dickenson | Project Syndicate | December 21, 2012
{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
 |
Infographics | More... |
Infographic: Could gut bacteria help us diagnose and treat diseases? This is on the horizon thanks to CRISPR gene editing
Humans are never alone. Even in a room devoid of other people, they are always in the company of billions ...
Most Popular
Viewpoint: The organic food industry is a $180 billion marketing fraud 
Is tilapia a human-made freak that we should avoid — or an evolutionary rockstar? 
How Wegovy and Ozempic could transform our food systems 
Frankenfoods? A ‘terrible word’ that could describe more foods than you might realize 
The increasingly bushy human family tree and five other paradigm-altering changes in our understanding of human evolution 
Blue soybeans? Orange wheat? How a gene-edited splash of color could make robotic weeding much easier 
How Freddie Mercury got his voice: It wasn’t his teeth 
Viewpoint: Will India embrace a second green revolution — one focused on sustainable agriculture instead of yield? 
Myth busting on pesticides: Despite demonization, organic farmers widely use them 
Curvy women advantage? Large buttocks may signal an evolutionary edge
